Trevi Therapeutics, Inc. (TRVI) is a clinical stage biopharmaceutical company which specializes in developing and commercializing innovative therapies for patients with serious or life-threatening diseases. The company is publicly listed and traded under the symbol "TRVI" on Nasdaq.
Founded in 2011, and based in New Haven, Connecticut, Trevi Therapeutics has dedicated its resources to unmet medical needs and has been working to provide revolutionary treatments for patients suffering from chronic pruritus and chronic cough. Chronic pruritus, or severe itching, and chronic cough are conditions that can significantly affect the quality of life, and at present, there are limited treatment options available.
Trevi Therapeutics' leading pipeline product is Haduvio™ (Nalbuphine ER), an extended-release oral tablet that targets a specific opioid receptor thought to reduce pruritus (itching) and cough. Haduvio is studied in several large patient populations, including Prurigo Nodularis (PN), chronic cough in Idiopathic Pulmonary Fibrosis (IPF), and chronic pruritus in Chronic Kidney Disease (CKD-aP).
Since its inception, Trevi has shown strong commitment to research and development. With top-notch scientists and researchers, the company undergoes stringent research methodologies and clinical trials to ensure the development of safe and effective treatments. In addition to the development of Haduvio, Trevi Therapeutics is also conducting preclinical studies on other drug candidates that target different pathologies.
Trevi's research approach and commitment to patient well-being have earned it recognition in the biotech sector. However, like all biotechnology companies, Trevi Therapeutics faces challenges in drug development, including regulatory hurdles, high development costs, and long lead times for drug approval and commercialization.
In its journey of over a decade, Trevi Therapeutics has evolved while undertaking significant efforts to contribute to the greater good of the medical community. The persistent dedication to developing novel treatments showcases the company’s goal of helping patients achieve a better quality of life, offering hope for those with otherwise limited options. Trevi continues to make strides in innovating new treatments, guided by its deep-seated commitment to making a positive impact on public health. In the coming years, the biopharmaceutical firm is poised to further its research and advance its development programs, aspiring to create medicines that truly make a difference in patients’ lives.